Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Inventory (2021 - 2025)

Apellis Pharmaceuticals filings provide 5 years of Inventory readings, the most recent being $142.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 75.12% year-over-year to $142.6 million, compared with a TTM value of $142.6 million through Dec 2025, up 75.12%, and an annual FY2025 reading of $142.6 million, up 75.12% over the prior year.
  • Inventory hit $142.6 million in Q4 2025 for Apellis Pharmaceuticals, up from $122.8 million in the prior quarter.
  • The five-year high for Inventory was $161.3 million in Q1 2024, with the low at $1.7 million in Q3 2021.
  • Median Inventory over the past 5 years was $85.7 million (2022), compared with a mean of $87.8 million.
  • The sharpest move saw Inventory surged 3463.09% in 2022, then crashed 48.87% in 2025.
  • Year by year, Inventory stood at $16.3 million in 2021, then skyrocketed by 426.3% to $85.7 million in 2022, then surged by 70.76% to $146.4 million in 2023, then plummeted by 44.38% to $81.4 million in 2024, then surged by 75.12% to $142.6 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $142.6 million, $122.8 million, and $121.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.